Hemidesmosome Mutations Contribute to the Onset and Severity of Acquired Autoimmune Bullous Diseases

Abstract

Hemidesmosomes are structures that anchor junctions between basal epithelial cells and the basement membrane, essential for skin integrity. Genetic mutation of hemidesmosomes was well documented for the inherited bullous disorder, but is rarely investigated for acquired bullous disorders. We designed a 16-gene targeted capture panel and sequenced 202 patients with hemidesmosomes-related acquired disorders and 123 healthy controls, identifying 114 pathogenic variants in 15 genes, including 20.2% novel variants. Clinical relevance (disease severity and outcome) and immunohistochemistry results demonstrated that ITGA6, LAMC2, and EPPK1 mutations significantly affected the expression of hemidesmosome-related proteins, compared with controls with non-carriers. Functional studies in Caenorhabditis elegans models with transmission electron microscopy and confocal microscopy demonstrated that ITGA6 (ina-1) mutation can disrupt the hemidesmosomes assembly network, such as cytolinker (vab-10a) and apical (mup-4) and basal (let-805), thereby disrupting the hemidesmosome structure. This represents a quantitative to qualitative change in pemphigoid disease. Transcriptomic and serum proteomic analyses further revealed that ITGA6 mutations perturb epithelial development and hemidesmosome integrity, with both missense/loss-of-function variants leading to activation of NOD-like receptor–NF-κB–TNF–pyroptosis signaling pathways. These findings highlight the critical role of hemidesmosome genetic variants in the development of not only inherited but also acquired autoimmune bullous disorders.

Keywords

acquired autoimmune disorders / Pemphigoid / Caenorhabditis elegans model / genetic mutation / hemidesmosome / skin anchor junctions

References

[1] L. Nahidiazar, M. Kreft, B. van den Broek, et al., “The Molecular Architecture of Hemidesmosomes, as Revealed With Super-Resolution Microscopy,” Journal of Cell Science 128, no. 20 (2015): 3714–3719.

[2] G. Walko, M. J. Castañón, and G. Wiche, “Molecular Architecture and Function of the Hemidesmosome,” Cell and Tissue Research 360, no. 2 (2015): 363–378.

[3] L. M. Sterk, C. A. Geuijen, L. C. Oomen, J. Calafat, H. Janssen, and A. Sonnenberg, “The Tetraspan Molecule CD151, a Novel Constituent of Hemidesmosomes, Associates With the Integrin alpha6beta4 and May Regulate the Spatial Organization of Hemidesmosomes,” Journal of Cell Biology 149, no. 4 (2000): 969–982.

[4] E. Laffitte, B. Favre, L. Fontao, et al., “Plectin, an Unusual Target Antigen in Bullous Pemphigoid,” British Journal of Dermatology 144, no. 1 (2001): 136–138.

[5] J. A. Manso, M. Gómez-Hernández, A. Carabias, et al., “Integrin α6β4 Recognition of a Linear Motif of Bullous Pemphigoid Antigen BP230 Controls Its Recruitment to Hemidesmosomes,” Structure (London, England) 27, no. 6 (2019): 952–964.e6.

[6] F. Van den Bergh, S. L. Eliason, and G. J. Giudice, “Type XVII Collagen (BP180) Can Function as a Cell-Matrix Adhesion Molecule via Binding to Laminin 332,” Matrix Biology 30, no. 2 (2011): 100–108.

[7] K. Wilhelmsen, S. H. Litjens, and A. Sonnenberg, “Multiple Functions of the Integrin alpha6beta4 in Epidermal Homeostasis and Tumorigenesis,” Molecular and Cellular Biology 26, no. 8 (2006): 2877–2886.

[8] M. A. Stepp, S. Spurr-Michaud, A. Tisdale, J. Elwell, and I. K. Gipson, “Alpha 6 Beta 4 Integrin Heterodimer Is a Component of Hemidesmosomes,” PNAS 87, no. 22 (1990): 8970–8974.

[9] J. D. Fine, “Epidemiology of Inherited Epidermolysis Bullosa Based on Incidence and Prevalence Estimates from the National Epidermolysis Bullosa Registry,” JAMA Dermatology 152, no. 11 (2016): 1231–1238.

[10] H. Schumann, D. Kiritsi, M. Pigors, et al., “Phenotypic Spectrum of Epidermolysis Bullosa Associated With α6β4 Integrin Mutations,” British Journal of Dermatology 169, no. 1 (2013): 115–124.

[11] R. W. Groves, L. Liu, P. J. Dopping-Hepenstal, et al., “A Homozygous Nonsense Mutation Within the Dystonin Gene Coding for the Coiled-Coil Domain of the Epithelial Isoform of BPAG1 Underlies a New Subtype of Autosomal Recessive Epidermolysis Bullosa Simplex,” Journal of Investigative Dermatology 130, no. 6 (2010): 1551–1557.

[12] L. Guerra, A. G. Condorelli, P. Fortugno, et al., “Epidermolysis Bullosa (EB) Acquisita in an Adult Patient With Previously Unrecognized Mild Dystrophic EB and Biallelic COL7A1 Mutations,” Acta Dermato-Venereologica 98, no. 4 (2018): 411–415.

[13] F. Schauer, A. Nyström, M. Kunz, et al., “Case Report: Diagnostic and Therapeutic Challenges in Severe Mechanobullous Epidermolysis Bullosa Acquisita,” Frontiers in Immunology 13 (2022): 883967.

[14] I. Turcan, A. M. Pasmooij, P. C. van den Akker, et al., “Heterozygosity for a Novel Missense Mutation in the ITGB4 Gene Associated with Autosomal Dominant Epidermolysis Bullosa,” JAMA Dermatology 152, no. 5 (2016): 558–562.

[15] S. Egami, J. Yamagami, and M. Amagai, “Autoimmune Bullous Skin Diseases, Pemphigus and Pemphigoid,” Journal of Allergy and Clinical Immunology 145, no. 4 (2020): 1031–1047.

[16] C. D. Sadik, E. Schmidt, D. Zillikens, and T. Hashimoto, “Recent Progresses and Perspectives in Autoimmune Bullous Diseases,” Journal of Allergy and Clinical Immunology 145, no. 4 (2020): 1145–1147.

[17] L. Lu, L. Chen, Y. Xu, and A. Liu, “Global Incidence and Prevalence of Bullous Pemphigoid: A Systematic Review and Meta-Analysis,” Journal of Cosmetic Dermatology 21, no. 10 (2022): 4818–4835.

[18] K. Kridin, D. Kneiber, E. H. Kowalski, M. Valdebran, and K. T. Amber, “Epidermolysis Bullosa Acquisita: A Comprehensive Review,” Autoimmunity Reviews 18, no. 8 (2019): 786–795.

[19] C. M. Montagnon, S. N. Tolkachjov, D. F. Murrell, M. J. Camilleri, and J. S. Lehman, “Subepithelial Autoimmune Blistering Dermatoses: Clinical Features and Diagnosis,” Journal of the American Academy of Dermatology 85, no. 1 (2021): 1–14.

[20] C. Pagliarello, C. Feliciani, and C. R. Girardelli, “Linear Immunoglobulin-A Bullous Dermatosis,” JAMA Dermatology 157, no. 2 (2021): 221.

[21] T. Reunala, K. Hervonen, and T. Salmi, “Dermatitis Herpetiformis: An Update on Diagnosis and Management,” American Journal of Clinical Dermatology 22, no. 3 (2021): 329–338.

[22] L. S. Chan, M. A. Dorman, A. Agha, T. Suzuki, K. D. Cooper, and K. Hashimoto, “Pemphigoid Vegetans Represents a Bullous Pemphigoid Variant. Patient's IgG Autoantibodies Identify the Major Bullous Pemphigoid Antigen,” Journal of the American Academy of Dermatology 28, no. 2 Pt 2 (1993): 331–335.

[23] S. Hiroyasu, T. Ozawa, H. Kobayashi, et al., “Bullous Pemphigoid IgG Induces BP180 Internalization via a Macropinocytic Pathway,” American Journal of Pathology 182, no. 3 (2013): 828–840.

[24] H. Iwata, N. Kamio, Y. Aoyama, et al., “IgG From Patients With Bullous Pemphigoid Depletes Cultured Keratinocytes of the 180-kDa Bullous Pemphigoid Antigen (Type XVII Collagen) and Weakens Cell Attachment,” Journal of Investigative Dermatology 129, no. 4 (2009): 919–926.

[25] T. Sasaoka, H. Ujiie, W. Nishie, et al., “Intravenous IgG Reduces Pathogenic Autoantibodies, Serum IL-6 Levels, and Disease Severity in Experimental Bullous Pemphigoid Models,” Journal of Investigative Dermatology 138, no. 6 (2018): 1260–1267.

[26] Y. Sun, H. Liu, Z. Wang, et al., “The HLA-DQB1*03:01 Is Associated With Bullous Pemphigoid in the Han Chinese Population,” Journal of Investigative Dermatology 138, no. 8 (2018): 1874–1877.

[27] Y. Sun, Y. Lin, B. Yang, et al., “The HLA Alleles B*0801 and DRB1*0301 Are Associated With Dermatitis Herpetiformis in a Chinese Population,” Journal of Investigative Dermatology 136, no. 2 (2016): 530–532.

[28] C. Zumelzu, C. Le Roux-Villet, and P. Loiseau, “Black Patients of African Descent and HLA-DRB1*15:03 Frequency Overrepresented in Epidermolysis Bullosa Acquisita,” Journal of Investigative Dermatology 131, no. 12 (2011): 2386–2393.

[29] L. Li, L. Sun, G. Yu, et al., “A Celiac Gene HLA-DQB1∗02:01 Is Associated With Linear IgA Bullous Dermatosis in the Chinese Population,” Journal of Investigative Dermatology 144, no. 3 (2024): 713–717.

[30] J. Y. W. Lee and J. A. McGrath, “Mutations in Genes Encoding Desmosomal Proteins: Spectrum of Cutaneous and Extracutaneous Abnormalities,” British Journal of Dermatology 184, no. 4 (2021): 596–605.

[31] A. Verkerk, D. Andrei, M. Vermeer, et al., “Disruption of TUFT1, a Desmosome-Associated Protein, Causes Skin Fragility, Woolly Hair, and Palmoplantar Keratoderma,” Journal of Investigative Dermatology 144, no. 2 (2024): 284–295.e16.

[32] R. M. Cabral, D. Tattersall, V. Patel, et al., “The DSPII Splice Variant Is Crucial for Desmosome-Mediated Adhesion in HaCaT Keratinocytes,” Journal of Cell Science 125, no. Pt 12 (2012): 2853–2861.

[33] T. B. Rasmussen, P. H. Nissen, J. Palmfeldt, et al., “Truncating Plakophilin-2 Mutations in Arrhythmogenic Cardiomyopathy Are Associated With Protein Haploinsufficiency in both Myocardium and Epidermis,” Circulation: Cardiovascular Genetics 7, no. 3 (2014): 230–240.

[34] M. Vallverdú-Prats, R. Brugada, and M. Alcalde, “Premature Termination Codon in 5' Region of Desmoplakin and Plakoglobin Genes May Escape Nonsense-Mediated Decay Through the Reinitiation of Translation,” International Journal of Molecular Sciences 23, no. 2 (2022): 656.

[35] Y. Zhang, B. J. Hwang, Z. Liu, et al., “BP180 dysfunction Triggers Spontaneous Skin Inflammation in Mice,” PNAS 115, no. 25 (2018): 6434–6439.

[36] J. Kroeger, E. Hoppe, C. Galiger, C. Has, and C. W. Franzke, “Amino Acid Substitution in the C-Terminal Domain of Collagen XVII Reduces Laminin-332 Interaction Causing Mild Skin Fragility With Atrophic Scarring,” Matrix Biology 80 (2019): 72–84.

[37] Y. Zhang, W. Li, L. Li, et al., “Structural Damage in the C. elegans Epidermis Causes Release of STA-2 and Induction of an Innate Immune Response,” Immunity 42, no. 2 (2015): 309–320.

[38] C. Gally, H. Zhang, and M. Labouesse, “Functional and Genetic Analysis of VAB-10 Spectraplakin in Caenorhabditis elegans,” Methods in Enzymology 569 (2016): 407–430.

[39] L. Hong, T. Elbl, J. Ward, et al., “MUP-4 Is a Novel Transmembrane Protein with Functions in Epithelial Cell Adhesion in Caenorhabditis elegans,” Journal of Cell Biology 154, no. 2 (2001): 403–414.

[40] R. Fu, X. Jiang, Z. Huang, and H. Zhang, “The Spectraplakins of Caenorhabditis elegans: Cytoskeletal Crosslinkers and Beyond,” Seminars in cell & developmental biology 69 (2017): 58–68.

[41] A. Bardhan, L. Bruckner-Tuderman, I. L. C. Chapple, et al., “Epidermolysis Bullosa,” Nature Reviews Disease Primers 6, no. 1 (2020): 78.

[42] A. Diociaiuti, E. Pisaneschi, S. Rossi, et al., “Autosomal Recessive Epidermolysis Bullosa Simplex due to EXPH5 Mutation: Neonatal Diagnosis of the First Italian Case and Literature Review,” Journal of the European Academy of Dermatology and Venereology 34, no. 11 (2020): e694–e697.

[43] A. L. Hérissé, A. Charlesworth, N. Bellon, et al., “Genotypic and Phenotypic Analysis of 34 Cases of Inherited Junctional Epidermolysis Bullosa Caused by COL17A1 Mutations,” British Journal of Dermatology 184, no. 5 (2021): 960–962.

[44] L. Samuelov, O. Sarig, R. M. Harmon, et al., “Desmoglein 1 Deficiency Results in Severe Dermatitis, Multiple Allergies and Metabolic Wasting,” Nature Genetics 45, no. 10 (2013): 1244–1248.

[45] W. Nishie, “Collagen XVII Processing and Blistering Skin Diseases,” Acta Dermato-Venereologica 100, no. 5 (2020): adv00054.

[46] M. Wada, W. Nishie, H. Ujiie, et al., “Epitope-Dependent Pathogenicity of Antibodies Targeting a Major Bullous Pemphigoid Autoantigen Collagen XVII/BP180,” Journal of Investigative Dermatology 136, no. 5 (2016): 938–946.

[47] M. Sonawane, H. Martin-Maischein, and H. Schwarz, “Nüsslein-Volhard C. Lgl2 and E-Cadherin Act Antagonistically to Regulate Hemidesmosome Formation During Epidermal Development in Zebrafish,” Development (Cambridge, England) 136, no. 8 (2009): 1231–1240.

[48] E. Hintermann and V. Quaranta, “Epithelial Cell Motility on Laminin-5: Regulation by Matrix Assembly, Proteolysis, Integrins and erbB Receptors,” Matrix Biology 23, no. 2 (2004): 75–85.

[49] H. Kosumi, M. Watanabe, S. Shinkuma, et al., “Wnt/β-Catenin Signaling Stabilizes Hemidesmosomes in Keratinocytes,” Journal of Investigative Dermatology 142, no. 6 (2022): 1576–1586.e2.

[50] J. Koster, D. Geerts, B. Favre, L. Borradori, and A. Sonnenberg, “Analysis of the Interactions Between BP180, BP230, Plectin and the Integrin alpha6beta4 Important for Hemidesmosome Assembly,” Journal of Cell Science 116, no. Pt 2 (2003): 387–399.

[51] M. M. Santoro, G. Gaudino, and P. C. Marchisio, “The MSP Receptor Regulates alpha6beta4 and alpha3beta1 Integrins via 14-3-3 Proteins in Keratinocyte Migration,” Developmental Cell 5, no. 2 (2003): 257–271.

[52] H. Zahreddine, H. Zhang, M. Diogon, Y. Nagamatsu, and M. Labouesse, “CRT-1/Calreticulin and the E3 Ligase EEL-1/HUWE1 Control Hemidesmosome Maturation in C. elegans Development,” Current Biology 20, no. 4 (2010): 322–327.

[53] I. Turcan and M. F. Jonkman, “Blistering Disease: Insight From the Hemidesmosome and Other Components of the Dermal-Epidermal Junction,” Cell and Tissue Research 360, no. 3 (2015): 545–569.

[54] H. Zhang and M. Labouesse, “The Making of Hemidesmosome Structures in Vivo,” Developmental Dynamics 239, no. 5 (2010): 1465–1476.

[55] J. R. McMillan and R. A. Eady, “Hemidesmosome Ontogeny in Digit Skin of the Human Fetus,” Archives of Dermatological Research 288, no. 2 (1996): 91–97.

[56] B. Fan and M. Wang, “Tofacitinib in Recalcitrant Bullous Pemphigoid: A Report of Seven Cases,” British Journal of Dermatology 188, no. 3 (2023): 432–434.

[57] I. Dixit, M. Mansilla-Polo, J. Kim, and P. Fernández-Peñas, “Successful Treatment of Refractory Dermatitis Herpetiformis with Upadacitinib,” International Journal of Dermatology (2025).

[58] J. W. Heo and Y. Lim, “Bullous Pemphigoid Treated With baricitinib as Steroid-Sparing Therapy for a Patient With Uncontrolled Diabetes,” JAAD Case Rep 57 (2025): 5–8.

[59] R. Abdat, R. A. Waldman, V. de Bedout, et al., “Dupilumab as a Novel Therapy for Bullous Pemphigoid: A Multicenter Case Series,” Journal of the American Academy of Dermatology 83, no. 1 (2020): 46–52.

[60] S. Muzumdar, L. A. Bibb, B. Sloan, M. Murphy, and M. W. Chang, “Letter in Reply: Linear IgA Bullous Dermatosis Treated with Dupilumab in a Pediatric Patient With Glucose-6-Phosphate Dehydrogenase Deficiency,” JAAD Case Rep 44 (2024): 44–46.

[61] S. Al-Khawaga, A. I. Ahmed, F. Al-Khawaja, et al., “Dermatitis Herpetiformis Successfully Treated With dupilumab,” JAAD Case Rep 61 (2025): 129–132.

[62] P. Joly, S. Baricault, A. Sparsa, et al., “Incidence and Mortality of Bullous Pemphigoid in France,” Journal of Investigative Dermatology 132, no. 8 (2012): 1998–2004.

[63] F. Wojnarowska, R. A. Marsden, B. Bhogal, and M. M. Black, “Chronic Bullous Disease of Childhood, Childhood Cicatricial Pemphigoid, and Linear IgA Disease of Adults. A Comparative Study Demonstrating Clinical and Immunopathologic Overlap,” Journal of the American Academy of Dermatology 19, no. 5 Pt 1 (1988): 792–805.

[64] J. H. Kim, Y. H. Kim, and S. C. Kim, “Epidermolysis Bullosa Acquisita: A Retrospective Clinical Analysis of 30 Cases,” Acta Dermato-Venereologica 91, no. 3 (2011): 307–312.

[65] T. J. M. Jordan, J. Chen, N. Li, et al., “The Eotaxin-1/CCR3 Axis and Matrix Metalloproteinase-9 Are Critical in Anti-NC16A IgE-Induced Bullous Pemphigoid,” Journal of Immunology 211, no. 8 (2023): 1216–1223.

[66] M. Riani, S. Le Jan, and J. Plée, “Bullous Pemphigoid Outcome Is Associated With CXCL10-Induced Matrix Metalloproteinase 9 Secretion From Monocytes and Neutrophils but Not Lymphocytes,” Journal of Allergy and Clinical Immunology 139, no. 3 (2017): 863–872.e3.

[67] Z. Liu, J. M. Shipley, T. H. Vu, et al., “Gelatinase B-Deficient Mice Are Resistant to Experimental Bullous Pemphigoid,” Journal of Experimental Medicine 188, no. 3 (1998): 475–482.

[68] M. Ståhle-Bäckdahl, M. Inoue, G. J. Guidice, and W. C. Parks, “92-kD Gelatinase Is Produced by Eosinophils at the Site of Blister Formation in Bullous Pemphigoid and Cleaves the Extracellular Domain of Recombinant 180-kD Bullous Pemphigoid Autoantigen,” Journal of Clinical Investigation 93, no. 5 (1994): 2022–2030.

[69] S. Verraes, Hornebeck, M. Polette, L. Borradori, and P. Bernard, “Respective Contribution of Neutrophil Elastase and Matrix Metalloproteinase 9 in the Degradation of BP180 (Type XVII Collagen) in Human Bullous Pemphigoid,” Journal of Investigative Dermatology 117, no. 5 (2001): 1091–1096.

[70] I. Shimanovich, S. Mihai, G. J. Oostingh, et al., “Granulocyte-Derived Elastase and Gelatinase B Are Required for Dermal-Epidermal Separation Induced by Autoantibodies From Patients With Epidermolysis Bullosa Acquisita and Bullous Pemphigoid,” Journal of Pathology 204, no. 5 (2004): 519–527.

[71] Z. Liu, X. Zhou, S. D. Shapiro, et al., “The Serpin Alpha1-Proteinase Inhibitor Is a Critical Substrate for Gelatinase B/MMP-9 in Vivo,” Cell 102, no. 5 (2000): 647–655.

[72] S. Hiroyasu, M. R. Zeglinski, H. Zhao, et al., “Granzyme B Inhibition Reduces Disease Severity in Autoimmune Blistering Diseases,” Nature Communications 12, no. 1 (2021): 302.

[73] V. Russo, T. Klein, D. J. Lim, et al., “Granzyme B Is Elevated in Autoimmune Blistering Diseases and Cleaves Key Anchoring Proteins of the Dermal-Epidermal Junction,” Scientific Reports 8, no. 1 (2018): 9690.

[74] Z. Liu, N. Li, L. A. Diaz, M. Shipley, R. M. Senior, and Z. Werb, “Synergy Between a Plasminogen Cascade and MMP-9 in Autoimmune Disease,” Journal of Clinical Investigation 115, no. 4 (2005): 879–887.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.